Affiliated Sites
  • Clinicians Network Payer Bioinformatics
Be The Match

Javascript disabled. This site requires JavaScript How to enable JavaScript.

You are using an outdated browser. Please upgrade your browser to improve your experience.

Close

NMDP

Be The Match
  • About Us
  • E-News Sign Up
  • My Cart
  • Transplant Indications and Outcomes
    • HLA Today
    • Disease-Specific Indications and Outcomes
      • AML - Adult
      • AML - Pediatric
      • ALL - Adult
      • ALL - Pediatric
      • Myelodysplastic Syndromes (MDS)
      • CML
      • CLL
      • NHL
      • Hodgkin Lymphoma
      • Multiple Myeloma
      • Severe Aplastic Anemia & Marrow Failure
      • Sickle Cell Disease
      • Immune Deficiency Diseases
      • Inherited Metabolic Disorders
      • Thalassemia
      • Other Diseases
      • Myeloproliferative Neoplasms
    • Additional Outcomes
      • Unrelated vs. Sibling Donor Outcomes
      • Older Patient Outcomes
      • Timing Impact on Outcomes
    • Eligibility
    • Referral Timing Guidelines
    • Order Kits
    • HLA Typing for Family Members
  • Transplant Therapy and Donor Matching
    • Cell Sources
    • HLA Typing and Matching
    • Donor or Cord Blood Search Process
      • Likelihood of Finding a Match
      • Preliminary Search Request
    • Jason Carter Clinical Trials Program
  • Post-Transplant Care
    • Early Complications
    • Vaccinations
    • Long-Term Care Guidelines
      • Pediatric Considerations
    • Chronic GVHD
      • Skin
      • Nails
      • Scalp and Body Hair
      • Eyes
      • Mouth
      • Lungs
      • Muscles, Fascia, Joints
      • Hematopoietic & Immune
      • GI Tract
      • Liver
      • Genitalia
      • Other
    • Post-Transplant Guidelines
  • Medical Education & Research
    • Browse News
    • Browse Research
      • Mismatched donor sources may fill an unmet need for patients without fully matched family or unrelated donors
      • Hematopoietic cell donor type may not impact quality of life post-transplant
      • Novel three-drug combination improves GVHD-free and relapse-free survival and relapse after allogeneic transplant
      • Long-term risks of hematological malignancy, autoimmune or thrombotic events do not differ in bone marrow and filgrastim-mobilized PBSC donors
      • Socioeconomic status but not race and ethnicity is likely associated with chronic GVHD outcomes after allogeneic HCT
      • Linkage across research databases may provide a more complete understanding of HCT patient outcomes
      • Race and ethnicity matching may not impact umbilical cord blood transplant patient outcomes
      • Factors associated with young adults opting out of donation for HCT may provide insights into donor availability
      • Alternative donor HCT may yield comparable outcomes and expand access for myelofibrosis patients
      • Younger matched unrelated donors may reduce relapse risk after allogeneic HCT compared to using older matched sibling donors
      • Allogeneic HCT may be a better option for older patients with AML than conventional consolidation therapy
    • Education Catalog
      • State of the Science in Ensuring a Donor for All
      • Predicting and Addressing Relapse After HCT
      • After the Results Quality of Life Pre- and Post-Transplant
      • Overcoming Challenges in Cell and Gene Therapy Trials Part 2
      • Overcoming Challenges in Cell and Gene Therapy Trials Part 1
    • Materials Catalog
    • HCT Presentation Slides
    • About Our Research
    • Transplant Enews
  • Resources
    • Patient Resources
    • Financial Resources
    • Obstetrician Resources
    • Technique Videos
    • Umbilical Cord Blood Collection Training for Public Donation
    • Local Provider Partnership Program
  • Patient Resources
  • Financial Resources
  • Obstetrician Resources
  • Technique Videos
  • Umbilical Cord Blood Collection Training for Public Donation
  • Local Provider Partnership Program

Local Provider Partnership Program


  • Resources
  • Local Provider Partnership Program
  • Email
  • Print This Page

Local Provider Partnership Program

Receive tailored clinical operations partner support for your hematology/oncology practice  

Your hematology/oncology practice may see dozens of patients or just a few who are candidates for cell therapy like hematopoietic cell transplantation (HCT). Either way, efficient pathways to treatment and collaboration with the patient’s transplant center are keys to optimal outcomes. 

A clinical operations partner from our Local Provider Partnership Program can help. A clinical operations partner based in your region works directly with your practice to:

  • Understand your practice’s unique challenges and develop timely, simplified solutions
  • Match your needs with the appropriate National Marrow Donor Program® (NMDP)/Be The Match® programs or support
  • Identify opportunities to positively impact patient care
  • Help you strengthen communication and collaboration with your transplant center network

Ultimately, your clinical operations partner is there to help you meet the unique needs of patients who need HCT or another cell therapy, remove barriers to cell therapy access and improve patient outcomes.

Connect with the clinical operations partner in your region.

 

Jaimie Rosario

‘A real game changer for many patients’

“I love partnering with our hematology/oncology practices to ease patient and physician concerns about barriers that make getting to a cell therapy consult challenging.

Knowing there is a team from the NMDP/Be The Match that is there to help streamline early HLA typing and provide support to overcome non-HLA barriers has been a real game changer for many patients and physicians.”

Jaimie Rosario
Clinical Operations Partner – Southern California
NMDP/Be The Match

 

Tailored support to meet your specific needs  

Hematology/oncology practices have different needs than transplant centers. But all have the same goal: to provide the best treatment and outcomes for patients when they need it most.

Your clinical operations partner will take the time to learn about your needs, and those of your patients. They’ll help you understand which NMDP/Be The Match services and support can best meet your needs.

They can also help your practice get set up with programs like HLA Today, which allows your practice to initiate early unrelated and related donor searches and get ahead in a patient’s treatment timeline. 

Explore the wide array of free NMDP/Be The Match services and support available to your hematology/oncology practice. 

A bridge for improved collaboration with transplant centers  

Collaboration and communication between your hematology/oncology practice and the transplant center is critical to ensure optimal patient outcomes and experiences.

From patient diagnosis at your center through their return to your care after cell therapy, your clinical operations partner is here to help you strengthen collaboration and coordinated care with your transplant center network.

Your clinical operations partner can help facilitate opportunities to share expertise between your practice and transplant centers through avenues like regional roundtables on disease-specific topics or CME/CE webinars to help inform your clinical practice.

Request a time to connect with a clinical operations partner in your region.

Transplant center-specific guides for efficient referrals  

Have you ever had a patient to refer for HCT consultation, but didn’t have a contact at the transplant center? Or the information you have is out of date?

Your clinical operations partner can provide your practice with up-to-date Transplant Center Contact Guides for the transplant centers in your area. 

Each guide offers transplant center-specific steps for referral, a contact directory and other details that allow you to work more efficiently with the transplant center.

Your clinical operations partner works with your transplant centers to keep the guides accurate.

Jaimie Rosario

‘Uniquely positioned to bridge any gaps’

“As clinical operations partners, we understand there are many barriers when it comes to referring a patient for transplant. We aim to break down barriers early in the patient’s treatment journey.

Because we have relationships with both the community hematology/oncology practices and transplant centers, we’re uniquely positioned to bridge any gaps to help ensure patients are referred for consultation early.”

Mark Dotson
Clinical Operations Partner – Columbus, Ohio
NMDP/Be The Match

Get in touch with a local clinical operations partner  

The clinical operations partner in your region would be happy to connect with you to discuss how we can support your hematology/oncology practice.

Use the form to contact us. The clinical operations partner in your region will get in touch with you soon.

 

  • Email
  • Print This Page

Transplant Indications and Outcomes

  • HLA Today
  • Disease-Specific Indications and Outcomes
  • Additional Outcomes
  • Eligibility
  • Referral Timing Guidelines
  • Order Kits
  • HLA Typing for Family Members

Transplant Therapy and Donor Matching

  • Cell Sources
  • HLA Typing and Matching
  • Donor or Cord Blood Search Process
  • Jason Carter Clinical Trials Program

Resources

  • Patient Resources
  • Financial Resources
  • Obstetrician Resources
  • Technique Videos
  • Umbilical Cord Blood Collection Training for Public Donation
  • Local Provider Partnership Program

Contact Us

National Marrow Donor Program —
Entrusted and under contract to operate the C.W. Bill Young Cell Transplantation Program, including Be The Match Registry®.
Copyright © 1996-2023 National Marrow Donor Program. All Rights Reserved. Terms of Use | Privacy Policy | Trademark & Copyright